Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $185.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price objective boosted by Morgan Stanley from $183.00 to $185.00 in a research note published on Tuesday morning,Benzinga reports. They currently have an equal weight rating on the stock.

Several other equities analysts also recently commented on NBIX. Mizuho upgraded Neurocrine Biosciences to a “hold” rating in a research note on Wednesday, September 16th. Truist Financial raised their target price on Neurocrine Biosciences from $200.00 to $213.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $210.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday. Zacks Research lowered Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Finally, TD Cowen boosted their price objective on Neurocrine Biosciences from $200.00 to $220.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $202.32.

Neurocrine Biosciences Price Performance

NASDAQ NBIX opened at $159.76 on Tuesday. The stock has a market capitalization of $16.17 billion, a price-to-earnings ratio of 20.81, a PEG ratio of 0.74 and a beta of 0.36. Neurocrine Biosciences has a one year low of $122.14 and a one year high of $186.12. The business’s fifty day moving average is $147.04 and its 200-day moving average is $147.90.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, beating the consensus estimate of $1.91 by $1.38. The company had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.04 billion. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 23.39%. The firm’s revenue for the quarter was up 41.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.04 earnings per share. Research analysts expect that Neurocrine Biosciences will post 7.66 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Matt Abernethy sold 2,311 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the transaction, the chief financial officer directly owned 42,808 shares in the company, valued at approximately $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David W. Boyer sold 826 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the transaction, the insider owned 8,722 shares of the company’s stock, valued at $1,373,278.90. This trade represents a 8.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 18,137 shares of company stock valued at $2,829,332. Corporate insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in NBIX. Entrust Financial LLC boosted its stake in Neurocrine Biosciences by 62.9% in the third quarter. Entrust Financial LLC now owns 202 shares of the company’s stock worth $29,000 after buying an additional 78 shares in the last quarter. Raleigh Capital Management Inc. raised its stake in shares of Neurocrine Biosciences by 561.8% during the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock worth $32,000 after acquiring an additional 191 shares in the last quarter. Basecamp Wealth Advisors LLC lifted its holdings in shares of Neurocrine Biosciences by 582.9% in the 1st quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares during the last quarter. Cassaday & Co Wealth Management LLC bought a new stake in shares of Neurocrine Biosciences in the 1st quarter worth approximately $33,000. Finally, TrinityBridge Ltd purchased a new stake in shares of Neurocrine Biosciences in the 2nd quarter valued at $45,000. 92.59% of the stock is currently owned by hedge funds and other institutional investors.

More Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported third-quarter revenue of $1.12 billion, up 41% year over year and above estimates, with EPS of $3.29 versus a $1.91 consensus. The company also raised its 2026 INGREZZA net-sales outlook to $2.9–$2.925 billion, reinforcing the growth case for its leading product. Q3 results and outlook
• Positive Sentiment: New survey findings showed fewer work or school disruptions among adults with tardive dyskinesia after starting INGREZZA: the share reporting disruptions fell from 57% to 21%, and average missed days declined from 5.6 to 2.0 per month. The results may bolster confidence in the treatment’s patient benefits. INGREZZA survey findings
• Positive Sentiment: Analysts raised price targets following the earnings report, including Morgan Stanley, Canaccord Genuity, RBC and Piper Sandler. Guggenheim also lifted its target to $224 and maintained a Buy rating, adding to the supportive analyst backdrop. Guggenheim rating
• Neutral Sentiment: After a sharp post-earnings advance, some investors may be taking profits, which could weigh on the shares despite the strong operating update. A director’s sale of 300 shares was made under a pre-arranged trading plan and appears small relative to his remaining holdings.
• Negative Sentiment: A report flagged potential integration challenges and legacy liabilities related to Neurocrine’s Soleno acquisition, risks that could complicate the expected value from the deal. Soleno acquisition risks

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.